Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized, Double-blind, Active Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of Psilocybin in Treatment-resistant Major Depression

NCT04670081 is registered in ClinicalTrials.gov with Central Institute of Mental Health, Mannheim as lead sponsor.

NCT NCT04670081
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04670081 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized, Double-blind, Active Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of Psilocybin in Treatment-resistant Major Depression
Lead sponsor
Central Institute of Mental Health, Mannheim
Phase
Phase 2
Overall status
Completed
Start date
June 10, 2021
Completion date
December 11, 2024
Enrollment
144 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

treatment-resistant depression